APA (7th ed.) Citation

Cao, G., Wang, J., He, J., Hu, Y., Yang, H., Que, L., . . . Zhang, J. (2023). LZM008, a proposed tocilizumab biosimilar: Pharmacokinetics, safety, and immunogenicity profiles compared with ACTEMRA® in Chinese healthy male subjects. Frontiers in pharmacology, 14, 1111893. https://doi.org/10.3389/fphar.2023.1111893

Chicago Style (17th ed.) Citation

Cao, Guoying, et al. "LZM008, a Proposed Tocilizumab Biosimilar: Pharmacokinetics, Safety, and Immunogenicity Profiles Compared with ACTEMRA® in Chinese Healthy Male Subjects." Frontiers in Pharmacology 14 (2023): 1111893. https://doi.org/10.3389/fphar.2023.1111893.

MLA (9th ed.) Citation

Cao, Guoying, et al. "LZM008, a Proposed Tocilizumab Biosimilar: Pharmacokinetics, Safety, and Immunogenicity Profiles Compared with ACTEMRA® in Chinese Healthy Male Subjects." Frontiers in Pharmacology, vol. 14, 2023, p. 1111893, https://doi.org/10.3389/fphar.2023.1111893.